Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 ...

Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026Medtronic (NYSE: MDT) and Orchestra BioMed intend to pursue late-breaking ...

PolyPid (NASDAQ:PYPD) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the ...

Learn how a general ledger supports double-entry accounting, compiling vital transaction data for accurate financial reporting and analysis.

“Our QUELIMMUNE net revenue in the first quarter was $495,000, a solid increase of 69% from the first quarter of last year,” said (Senior Vice President of Commercial & Business Operations Tim Varacek ...

B cash runway to mid-2029, pivotal SCD & AATD programs, and attractive valuation—review risks and opportunities now.

Detailed price information for Alx Oncology Holdings Inc (ALXO-Q) from The Globe and Mail including charting and trades.

Detailed price information for Nexa Resources S.A. (NEXA-N) from The Globe and Mail including charting and trades.

Initiated NDA Submission to the FDA for D-PLEX₁₀₀ ; Completion Expected Imminently U.S. Commercial Partnership Discussions in Late ...

First Boric Acid Offtake Agreement -- 7,500 tons per year signed with a domestic and industrial boric acid end user, ...

Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") by the end of Q3 2026Medtronic (NYSE: MDT) and Orchestra BioMed intend to pursue late-breaking clin ...